The newest multiple sclerosis drug could be a boon for patients — and a threat to the multibillion-dollar business of Biogen Inc., the leading seller of MS treatments.
When regulators in March cleared the new drug, called Ocrevus and made by Genentech, it was the latest in a line of more than a dozen medicines that have emerged over the past two decades to treat MS. The neurological disease afflicts at least 400,000 Americans and more than 2.3 million people worldwide.
